Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says - WSJ

As reported by The Wall Street Journal

Company plans to refile its application for its gene therapy for a fatal brain disease after FDA dropped demands to give a placebo to some study subjects

▸ MARKET SAMACHAR ANALYSIS

Our editorial commentary, not the publisher's article body.

Regenxbio is set to refile its application for a gene therapy targeting a fatal brain disease. This follows the FDA dropping its demand for a placebo group in the study. This marks the third rare-disease drug to receive a second chance from the FDA, signaling positive momentum…

Regenxbio refiles gene therapy application.
FDA drops placebo study demands.
Third rare disease drug gets chance.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on The Wall Street Journal ↗

Market Samachar is a news aggregator. This article was originally published by The Wall Street Journal. Tap the button above to read the full story on their site.

Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says - WSJ

More from Market Samachar